Prenetics Announces Third Quarter 2024 Financial Results

1 year ago

Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand…

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

1 year ago

ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research,…

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

1 year ago

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel…

WORK Medical Technology Group LTD’s Subsidiary, Hangzhou Shanyou, Showcases Products at MEDICA Trade Fair 2024

1 year ago

Hangzhou, China, Nov. 27, 2024 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”),…

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

1 year ago

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

1 year ago

CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and…

Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

1 year ago

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic…

Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

1 year ago

CLEARWATER, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a…

Radiopharm Achieves Nasdaq Listing of American Depositary Shares

1 year ago

Trading under ticker symbol RADXComplements existing US shareholders (currently holding 21% of Radiopharm)No associated capital raisingModest admin & financial compliance…

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

1 year ago

The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy…